Investors
Investors

Message from CEO

“Key global products including XTANDI® continued to demonstrate steady growth in the first nine months of FY2017. We achieved many milestones including the acquisition of Mitobridge, Inc. in January 2018 by exercising the option right to acquire Mitobridge. The transaction accelerates Astellas' research and development in diseases associated with mitochondrial dysfunctions," said Yoshihiko Hatanaka, president and CEO, Astellas. "We remain committed to creating innovative medical solutions and delivering value for patients and all stakeholders, as we continue to advance our strategic plan by maximizing the value of our products, creating innovation and pursuing operational excellence.”

Stock Quotes(TSE 1st:4503)

View Stock Performance

IR Library

This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.

Read More

Stock & Rating Information

Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash divid...

Read More

Analyst Coverage

List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc

Read More

Cautionary Statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including sh...

Read More